I think it can correctly be labelled a synergistic business...

I think it can correctly be labelled a synergistic business opportunity distinct from the others in the IHL stable and a multi million dollar revenue earner annually - speed to marketlooks very well planned

Combine the TGA regulatory opportunity / P. Widdows commercial experience and business expertise / the psilocybin & mdma therapeutic treatment oportunity / the growing interest in the market for these drug candidates and the IHL clinical trial work - Mr B.Clark and the whole IHL team and looking very very tasty - and its' 'local' root tapping before international expansion


Big Pharma is moving on the space
'Psychedelics are only going to continue to move into the mainstream, said Simeon Schnapper, managing partner at JLS Fund, an investment firm that's made 22 deals in the space since 2019.
"Insurers, Big Pharma and biotech are already adjusting their strategies based on the overwhelming clinical evidence," Schnapper said.

Ken Belotsky from Negev Capital said that he's already started seeing M&A interest. "We believe that these companies will enter the market by acquiring the best startups in the space as soon as we see more progress in clinical trials," Belotsky said.

these guys are backing Filament health in their psychedelic development commercialisation program...no brainer imo
https://negevcap.com/

plenty more examples on the web for those interested

12.5 c for this hold on the market for this business value proposition developing in the psychedelic treatment space is nothing but a BUYING OPPORTUNITY = ridiculously cheap ....imo

also watching for the patents to drop on this drug pathway....they may appear under these additional business names et al so Ive expanded my search criteria ....guessing you're 3 steps ahead as usual


glah